Snow days extend reviews
Executive Summary
Due to the two-day federal government shutdown, review divisions have discretion to extend any PDUFA date coming due within 30 days of the shutdown (Jan. 25 & 26) by two days. Decisions will be made on a case-by-case basis, the agency said. Texas Biotechnology's Novastan (argatroban) is one product to have its review extended: the user fee review goal for FDA's priority review of the product for use in patients with heparin-induced thrombocytopenia syndrome was originally Feb. 16 and was extended to Feb. 18
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth